What’s Next For Castle Biosciences Stock? |
| November 11, 2021 | November 2021 Bond Updates |
|
The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its downbeat Q3 results. Castle Biosciences reported revenue of $23.5 million, slightly above the... |
| View more at: https://www.forbes.com/sites/greatspeculations/2021/11/11/whats-next-for-castle-biosciences-stock/ |